Clinical Trials Logo

B-cell Lymphoma Recurrent clinical trials

View clinical trials related to B-cell Lymphoma Recurrent.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04531046 Active, not recruiting - Clinical trials for B-Cell Lymphoma Refractory

Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

Start date: March 10, 2021
Phase: Phase 2
Study type: Interventional

This is a phase 2, open-label, multicenter study evaluating axicabtagene ciloleucel (axi-cel) as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL who are ineligible to receive Autologous Stem Cell Transplantation but eligible to receive CAR T-cell therapy.

NCT ID: NCT04304040 Active, not recruiting - Clinical trials for B-cell Lymphoma Refractory

A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

Start date: July 28, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Dose escalation and expansion phase I/IIa clinical study of recombinant humanized type II CD20 monoclonal antibody MIL62 injection combined with a novel selective Bruton Tyrosine Kinase(BTK) inhibitor Orelabrutinib in the treatment of recurrent/refractory CD20+B cell lymphoma

NCT ID: NCT04214886 Active, not recruiting - Clinical trials for B-cell Lymphoma Refractory

CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies

Start date: December 31, 2019
Phase: Phase 1
Study type: Interventional

In this protocol, the investigators hypothesize that modifying the process of producing CAR+ T-cells can help to improve responses and reduce toxicities. Building on previous in vitro studies that have shown successful production of CAR+ T-cells using a new production approach, the investigators are now studying the ability to produce these CAR+ T-cells and determine how well they work in the clinical setting.

NCT ID: NCT03664635 Active, not recruiting - Clinical trials for Non-Hodgkin's Lymphoma

MB-CART20.1 Lymphoma

Start date: September 25, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This trial is a phase I/II trial to assess safety, dose finding and feasibility of ex vivo generated MB-CART20.1 cells in patients with relapsed or refractory CD20 positive B-NHL.